The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Radioembolization for Hepatocellular Carcinoma Using Yttrium-90 Microspheres: A Comprehensive Report of Long-term Outcomes
Open accessAbstract
BACKGROUND & AIMS: Hepatocellular carcinoma (HCC) has limited treatment options; long-term outcomes following intra-arterial radiation are unknown. We assessed clinical outcomes of patients treated with intra-arterial yttrium-90 microspheres (Y90). METHODS: Patients with HCC (n = 291) were treated with Y90 as part of a single-center, prospective, longitudinal cohort study. Toxicities were recorded using the Common Terminology Criteria version 3.0. Response rate and time to progression (TTP) were determined using World Health Organization (WHO) and European Association for the Study of the Liver (EASL) guidelines. Survival by stage was assessed. Univariate/multivariate analyses were performed. RESULTS: A total of 526 treatments were administered (mean, 1.8; range, 1-5). Toxicities included fatigue (57%), pain (23%), and nausea/vomiting (20%); 19% exhibited grade 3/4 bilirubin toxicity. The 30-day mortality rate was 3%. Response rates were 42% and 57% based on WHO and EASL criteria, respectively. The overall TTP was 7.9 months (95% confidence interval, 6-10.3). Survival times differed between patients with Child-Pugh A and B disease (A, 17.2 months; B, 7.7 months; P = .002). Patients with Child-Pugh B disease who had portal vein thrombosis (PVT) survived 5.6 months (95% confidence interval, 4.5-6.7). Baseline age; sex; performance status; presence of portal hypertension; tumor distribution; levels of bilirubin, albumin, and alpha-fetoprotein; and WHO/EASL response rate predicted survival. CONCLUSIONS: Patients with Child-Pugh A disease, with or without PVT, benefited most from treatment. Patients with Child-Pugh B disease who had PVT had poor outcomes. TTP and overall survival varied by patient stage at baseline. These data can be used to design future Y90 trials and to describe Y90 as a potential treatment option for patients with HCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Global Cancer Statistics, 2002
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.2.74 · Cited by 18,196
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Reporting results of cancer treatment
Miller, A. B., Hoogstraten, B., Staquet, M., & Winkler, A. (1981) · Cancer · doi:10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6 · Cited by 7,793
Mazzaferro, V., Regalia, E., Doci, R., Andreola, S., Pulvirenti, A., Bozzetti, F., Montalto, F., Ammatuna, M., Morabito, A., & Gennari, L. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603143341104 · Cited by 7,186
Management of Hepatocellular Carcinoma *
Bruix, J., & Sherman, M. (2005) · Hepatology · doi:10.1002/hep.20933 · Cited by 5,857
Cheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference
Bruix, J., Sherman, M., Llovet, J. M., Beaugrand, M., Lencioni, R., Burroughs, A. K., Christensen, E., Pagliaro, L., Colombo, M., & Rodés, J. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00130-1 · Cited by 4,089
Llovet, J. M., Burroughs, A., & Bruix, J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14964-1 · Cited by 3,608
Llovet, J. M., Real, M. I., Montaña, X., Planas, R., Coll, S., Aponte, J., Ayuso, C., Sala, M., Muchart, J., Solà, R., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08649-x · Cited by 3,494
Lo, C.-M., Ngan, H., Tso, W.-K., Liu, C.-L., Lam, C.-M., Poon, R. T.-P., Fan, S.-T., & Wong, J. (2002) · Hepatology · doi:10.1053/jhep.2002.33156 · Cited by 2,613
Primary liver cancer: Worldwide incidence and trends
Bosch, F. X., Ribes, J., Díaz, M., & Cléries, R. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.09.011 · Cited by 2,477
Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma
Llovet, J. M., Di Bisceglie, A. M., Bruix, J., Kramer, B. S., Lencioni, R., Zhu, A. X., Sherman, M., Schwartz, M., Lotze, M., Talwalkar, J., et al. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djn134 · Cited by 1,653
Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer
Tol, J., Koopman, M., Cats, A., Rodenburg, C. J., Creemers, G. J. M., Schrama, J. G., Erdkamp, F. L. G., Vos, A. H., van Groeningen, C. J., Sinnige, H. A. M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808268 · Cited by 1,341
Phase II Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Abou-Alfa, G. K., Schwartz, L., Ricci, S., Amadori, D., Santoro, A., Figer, A., De Greve, J., Douillard, J.-Y., Lathia, C., Schwartz, B., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.3441 · Cited by 1,195
Hecht, J. R., Mitchell, E., Chidiac, T., Scroggin, C., Hagenstad, C., Spigel, D., Marshall, J., Cohn, A., McCollum, D., Stella, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8135 · Cited by 850
Takayasu, K., Arii, S., Ikai, I., Omata, M., Okita, K., Ichida, T., Matsuyama, Y., Nakanuma, Y., Kojiro, M., Makuuchi, M., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.05.021 · Cited by 810
Extrahepatic Metastases of Hepatocellular Carcinoma
Katyal, S., Oliver, J. H., Peterson, M. S., Ferris, J. V., Carr, B. S., & Baron, R. L. (2000) · Radiology · doi:10.1148/radiology.216.3.r00se24698 · Cited by 742
Arii, S., Yamaoka, Y., Futagawa, S., Inoue, K., Kobayashi, K., Kojiro, M., Makuuchi, M., Nakamura, Y., Okita, K., & Yamada, R. (2000) · Hepatology · doi:10.1053/jhep.2000.20456 · Cited by 725
The Barcelona approach: Diagnosis, staging, and treatment of hepatocellular carcinoma
Llovet, J. M., Fuster, J., & Bruix, J. (2004) · Liver Transplantation · doi:10.1002/lt.20034 · Cited by 700
Salem, R., & Thurston, K. G. (2006) · Journal of Vascular and Interventional Radiology · doi:10.1097/01.rvi.0000233785.75257.9a · Cited by 699
Self-citationLok, A. S., Seeff, L. B., Morgan, T. R., di Bisceglie, A. M., Sterling, R. K., Curto, T. M., Everson, G. T., Lindsay, K. L., Lee, W. M., Bonkovsky, H. L., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2008.09.014 · Cited by 651
Sala, M., Llovet, J. M., Vilana, R., Bianchi, L., Solé, M., Ayuso, C., Brú, C., & Bruix, J. (2004) · Hepatology · doi:10.1002/hep.20465 · Cited by 447
Kennedy, A. S., Nutting, C., Coldwell, D., Gaiser, J., & Drachenberg, C. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2004.09.004 · Cited by 407
Salem, R., Lewandowski, R. J., Atassi, B., Gordon, S. C., Gates, V. L., Barakat, O., Sergie, Z., Wong, C.-Y. O., & Thurston, K. G. (2005) · Journal of Vascular and Interventional Radiology · doi:10.1097/01.rvi.0000184594.01661.81 · Cited by 404
Self-citationLu, D. S. K., Yu, N. C., Raman, S. S., Limanond, P., Lassman, C., Murray, K., Tong, M. J., Amado, R. G., & Busuttil, R. W. (2005) · Radiology · doi:10.1148/radiol.2343040153 · Cited by 387
Disparities in Liver Transplantation Before and After Introduction of the MELD Score
Moylan, C. A. (2008) · JAMA · doi:10.1001/jama.2008.720 · Cited by 364
Yttrium-90 microspheres for the treatment of hepatocellular carcinoma
Geschwind, J. F. H., Salem, R., Carr, B. I., Soulen, M. C., Thurston, K. G., Goin, K. A., van Buskirk, M., Roberts, C. A., & Goin, J. E. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.09.034 · Cited by 355
Self-citationKulik, L. M., Atassi, B., van Holsbeeck, L., Souman, T., Lewandowski, R. J., Mulcahy, M. F., Hunter, R. D., Nemcek, A. A., Abecassis, M. M., Haines, K. G., et al. (2006) · Journal of Surgical Oncology · doi:10.1002/jso.20609 · Cited by 333
Self-citationLeung, T. W. T., Lau, W.-Y., Ho, S. K. W., Ward, S. C., Chow, J. H. S., Chan, M. S. Y., Metreweli, C., Johnson, P. J., & Li, A. K. C. (1995) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(95)00039-3 · Cited by 315
A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation
Yao, F. Y., Hirose, R., LaBerge, J. M., Davern, T. J., Bass, N. M., Kerlan, R. K., Merriman, R., Feng, S., Freise, C. E., Ascher, N. L., et al. (2005) · Liver Transplantation · doi:10.1002/lt.20526 · Cited by 288
Riaz, A., Kulik, L., Lewandowski, R. J., Ryu, R. K., Giakoumis Spear, G., Mulcahy, M. F., Abecassis, M., Baker, T., Gates, V., Nayar, R., et al. (2009) · Hepatology · doi:10.1002/hep.22747 · Cited by 260
Self-citationSato, K., Lewandowski, R. J., Bui, J. T., Omary, R., Hunter, R. D., Kulik, L., Mulcahy, M., Liu, D., Chrisman, H., Resnick, S., et al. (2006) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-005-0171-4 · Cited by 237
Self-citationPrognostic factors of hepatocellular carcinoma in the west: A multivariate analysis in 206 patients
Calvet, X., Bruix, J., Ginés, P., Bru, C., Sole, M., Vilana, R., & Rodés, J. (1990) · Hepatology · doi:10.1002/hep.1840120422 · Cited by 226
Maddala, Y. K., Stadheim, L., Andrews, J. C., Burgart, L. J., Rosen, C. B., Kremers, W. K., & Gores, G. (2004) · Liver Transplantation · doi:10.1002/lt.20099 · Cited by 214
Goin, J. E., Salem, R., Carr, B. I., Dancey, J. E., Soulen, M. C., Geschwind, J. F. H., Goin, K., Van Buskirk, M., & Thurston, K. (2005) · Journal of Vascular and Interventional Radiology · doi:10.1097/01.rvi.00001142592.89564.f9 · Cited by 170
Self-citationInflammation, HCC and sex: IL-6 in the centre of the triangle
Prìeto, J. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2007.11.007 · Cited by 149
Imaging of Hepatocellular Carcinoma After Treatment with Yttrium-90 Microspheres
Keppke, A. L., Salem, R., Reddy, D. H., et al. (2007) · American Journal of Roentgenology · doi:10.2214/ajr.06.0706 · Cited by 123
Self-citationRhee, T. K., Naik, N. K., Deng, J., Atassi, B., Mulcahy, M. F., Kulik, L., Ryu, R. K., Miller, F. H., Larson, A. C., Salem, R., et al. (2008) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2008.05.002 · Cited by 117
Self-citationGoin, J. E., Salem, R., Carr, B. I., Dancey, J. E., Soulen, M. C., Geschwind, J.-F. H., Goin, K., Buskirk, M. V., & Thurston, K. G. (2005) · Journal of Vascular and Interventional Radiology · doi:10.1097/01.rvi.0000142602.79459.90 · Cited by 113
Self-citationConformal chemoradiation for primary and metastatic liver malignancies
Dawson, L. A., McGinn, C. J., & Lawrence, T. S. (2003) · Seminars in Surgical Oncology · doi:10.1002/ssu.10043 · Cited by 36
Cited by
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00240-3 · Cited by 7,055
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
“Around 20% of patients present liver-related toxicity and 3% treatment-related death [297].”
BackgroundForner, A., Llovet, J. M., & Bruix, J. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61347-0 · Cited by 4,022
El-Serag, H. B. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1001683 · Cited by 3,529
Metadata
- Authors
- Salem, R., Lewandowski, R. J., Mulcahy, M. F., Riaz, A., Ryu, R. K., Ibrahim, S., Atassi, B., Baker, T., Gates, V., Miller, F. H., Sato, K. T., Wang, E., Gupta, R., Benson, A. B., Newman, S. B., Omary, R. A., Abecassis, M., & Kulik, L.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2010-01
- Volume
- 138
- Issue
- 1
- Pages
- 52-64
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W1998417832
- Cited by
- 1,074
- References
- 44
- FWCI
- 31.49
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.